Fidelity Management & Research Co has recently announced that it has increased stake in Roivant Sciences Ltd (NASDAQ:ROIV) by 8.10%. After grabbing 38.88 million shares, the institutional investor is now in possession of 2.91 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 4.84% having worth around $371.72 million. Moreover, Morgan Stanley Investment Managem increased its share by 6.0 million to have a control over 17.77 million shares. And BlackRock Fund Advisors raised its holdings to 5.49 million shares by acquiring 16.28 million shares or 2.03% of the stake.
Roivant Sciences Ltd (ROIV) concluded trading on 01/04/24 at a closing price of $10.82, with 5.37 million shares of worth about $58.14 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 1.60% during that period and on Thursday the price saw a loss of about -0.37%. Currently the company’s common shares owned by public are about 760.14M shares, out of which, 546.67M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the stock later moved at a day high price of 10.99, or with a loss of -0.37%. Stock saw a price change of -6.56% in past 5 days and over the past one month there was a price change of 8.85%. Year-to-date (YTD), ROIV shares are showing a performance of -3.65% which increased to 51.33% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $6.59 but also hit the highest price of $13.24 during that period. The average intraday trading volume for Roivant Sciences Ltd shares is 5.94 million. The stock is currently trading 1.34% above its 20-day simple moving average (SMA20), while that difference is up 12.02% for SMA50 and it goes to 9.43% higher than SMA200.
Fidelity Management & Research Co acquired 38.88 million shares of Roivant Sciences Ltd having value of about $371.72 million. Data submitted at the U.S SEC by Fidelity Management & Research Co revealed that the firm now holds 2.91 million shares in the company valued at close to $31523593.92, or have control over 8.10% stake in the company. Roivant Sciences Ltd (NASDAQ: ROIV) currently have 760.14M outstanding shares and institutions hold larger chunk of about 56.32% of that. Holding of mutual funds in the company is about 42.89% while other institutional holders and individual stake holders have control over 52.48% and 13.43% of the stake respectively.
The stock has a current market capitalization of $8.70B and its 3Y-monthly beta is at 1.36. It has posted earnings per share of -$1.32 in the same period. It has Quick Ratio of 5.82 while making debt-to-equity ratio of 0.53. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ROIV, volatility over the week remained 3.44% while standing at 3.79% over the month.
Analysts are in expectations that Roivant Sciences Ltd (ROIV) stock would likely to be making an EPS of -$0.32 in the current quarter, while forecast for next quarter EPS is -$0.32 and it is -$1.15 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.38 which is -$0.26 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.49 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -16.99% while it is estimated to increase by 15.87% in next year.
Analysts at 11 brokerage firms have issued recommendations for the Roivant Sciences Ltd (ROIV)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.18. Out of those 11 Wall Street analysts, 10 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Deutsche Bank on December 12, 2023 offering a Buy rating for the stock and assigned a target price of $14 to it.
